Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide

I.S. Nijhof, J.J.L. van Bueren, B. van Kessel, P. Andre, Y. Morel, H.M. Lokhorst, N.W.C.J. van de Donk, P.W.H.I. Parren, T. Mutis

Research output: Contribution to journalArticleAcademicpeer-review

90 Citations (Scopus)
Original languageUndefined/Unknown
Pages (from-to)263-268
Issue number2
Publication statusPublished - 2015

Cite this